CMV Prevention and Treatment in Transplantation: What's New in 2019.

ABSTRACT:

Purpose of review

Transplant recipients are at risk for cytomegalovirus (CMV) infection and associated morbidity and mortality. We summarize recently introduced or currently investigated modalities for prevention and treatment of CMV infection in hematopoietic cell (HCT) and solid organ transplant (SOT) recipients.

Recent findings

Letermovir was recently approved for CMV prevention in HCT recipients. Data from real world studies support its role to improve outcomes in this population. Letermovir is currently under investigation for broader patient populations and indications. Maribavir is in late stages of development for CMV treatment and may provide a safer alternative to currently available anti-CMV drugs. Promising CMV vaccine candidates and adoptive cell therapy approac

SUBMITTER: Stern A 

PROVIDER: S-EPMC8142836 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature